Clinical Trials Browser

Lymphoma, Mantle-Cell

NCT04973605 2026-04-22

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Phase 1/2 Recruiting

246 enrolled

Plasma cell

Multiple Myeloma

NCT05006716 2026-04-22

CaDAnCe-101

Phase 1/2 Recruiting

614 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05099003 2026-04-22

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Phase 1/2 Recruiting

132 enrolled

CNS

Glioma

NCT05130801 2026-04-22

A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery

Phase 1/2 Recruiting

55 enrolled

Breast

Breast Neoplasms

NCT05455619 2026-04-22

Amelia-1

Phase 1/2 Recruiting

52 enrolled

Breast

Breast Neoplasms, Hyperglycemia, Hyperinsulinism, Insulin Resistance

NCT05470491 2026-04-22

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

Phase 1/2 Recruiting

265 enrolled

Other hematologic neoplasm

Acquired Immunodeficiency Syndrome, Hematologic Neoplasms

NCT06303193 2026-04-22

Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

Phase 1/2 Recruiting

160 enrolled

Classical hematologyMyeloid

Anemia, Aplastic, Anemia, Refractory, with Excess of Blasts, Bone Marrow Diseases, Myelodysplastic Syndromes, Myeloproliferative Disorders

NCT06785636 2026-04-22

P300

Phase 1/2 Recruiting

252 enrolled

Genitourinary

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT06898450 2026-04-22

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

Phase 1/2 Recruiting

134 enrolled

Werner Syndrome, Microsatellite Instability

NCT06922591 2026-04-22

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Phase 1/2 Recruiting

183 enrolled

Thoracic

Lung Neoplasms

NCT07020221 2026-04-22

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Phase 1/2 Recruiting

295 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT07136779 2026-04-22

First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies

Phase 1/2 Recruiting

310 enrolled

Other solid neoplasm

Participants With Advanced Solid Tumor Malignancies

NCT07243470 2026-04-22

TARLATEM

Phase 1/2 Recruiting

70 enrolled

CNS

Glioma, Central Nervous System Neoplasms

NCT07299747 2026-04-22

Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors

Phase 1/2 Recruiting

255 enrolled

Other solid neoplasm

Participants With Advanced Solid Tumor Malignancies

NCT07332455 2026-04-22

First-Time-in-Human Study of GSK5471713 in Adults With mCRPC

Phase 1/2 Recruiting

54 enrolled

Genitourinary

Prostatic Neoplasms

NCT03919240 2026-04-21

CAR-T Cell Therapy Targeting to CD19 for R/R ALL

Phase 1/2 Recruiting

196 enrolled

LymphoidOther hematologic neoplasm

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03919292 2026-04-21

Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

Phase 1/2 Recruiting

83 enrolled

Gastrointestinal

Colonic Neoplasms, Pancreatic Neoplasms, Disease Progression

NCT04067336 2026-04-21

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Phase 1/2 Recruiting

263 enrolled 2 FDA

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04946370 2026-04-21

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

Phase 1/2 Recruiting

52 enrolled

Genitourinary

Prostatic Neoplasms

NCT05732831 2026-04-21

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Phase 1/2 Recruiting

225 enrolled

GastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Sarcoma, Cholangiocarcinoma, Neurofibrosarcoma

NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Phase 1/2 Recruiting

554 enrolled

CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

NCT06137144 2026-04-21

PRIMAVERA

Phase 1/2 Recruiting

161 enrolled

Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral

NCT06239272 2026-04-21

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Phase 1/2 Recruiting

139 enrolled

Plasma cellSarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

NCT06287775 2026-04-21